This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Paraxanthine

Well Researched

Caffeine's main active metabolite, sold direct as ENFINITY — what your liver makes anyway when you drink coffee, but skipping the parent…

Aliases (6)

1 · 7-dimethylxanthine · 17DMX · ENFINITY · paraXan · dimethylxanthine

TYPICAL DOSE

100-200mg

Daily

ROUTE

Oral (capsule)

Oral

CYCLE

2-4 days on, 3-5 days off

Continuous / daily

STORAGE

Room temp; cool dry place

Room temp

Overview

What is Paraxanthine?

Paraxanthine (1,7-dimethylxanthine) is the primary metabolite of caffeine in humans, formed by hepatic CYP1A2-mediated demethylation, and accounts for ~84% of caffeine's metabolic products. It is now sold as a standalone supplement (e.g., enfinity).

Key Benefits

Reported to provide caffeine-like alertness, focus, and physical performance benefits with reduced anxiety, jitters, and sleep disruption compared to caffeine. Studies show improved reaction time, working memory, and reasoning vs placebo and caffeine.

Mechanism of Action

Adenosine A1 and A2A receptor antagonist (similar to caffeine), increasing dopaminergic and cholinergic transmission. Also inhibits phosphodiesterase and increases intracellular cAMP, with weaker effects on benzodiazepine receptors and a more selective adenosine receptor profile than caffeine.

▸Brand options1 known

ENFINITY

StatusOTC supplement ingredient (US, GRAS for ENFINITY brand 2022); not scheduled; not on WADA prohibited list (treated as caffeine-class methylxanthine, on monitoring program)

Research Indications

Most Effective

Cyclic GMP-PDE5 inhibition

paraxanthine is a slightly stronger PDE5 inhibitor than caffeine in vitro, which has been speculated to contribute to its ergogenic profi…

Peptide Interactions

[l-theanine](l-theanine.md) (1:1 to 1:2 ratio, 200-400mg theanine per 200mg paraxanthine):

Synergistic

Same logic as the caffeine + theanine pairing. Theanine's alpha-wave / GABA-A modulation smooths any residual adrenergic edge while preserving the alerting e…

[l-tyrosine](l-tyrosine.md) (500mg-2g, 30-60 min before paraxanthine):

Synergistic

Mechanistic synergy parallel to caffeine + tyrosine. Paraxanthine's A2A blockade increases striatal DA tone → tyrosine supplies the precursor. PRN, not daily.

Citicoline / Alpha-GPC (V4 baseline):

Synergistic

Cholinergic + methylxanthine pairing is generally clean.

Caffeine on the same day:

Avoid

additive adenosine blockade. Pick one per day.

Other adenosine-receptor antagonists (KW-6356 if/when launched, theophylline-class compounds):

Avoid

additive, not synergistic.

High-dose other stimulants (amphetamine, methylphenidate, high-dose synephrine, yohimbine):

Avoid

cumulative sympathetic load.

[modafinil](modafinil.md) on day-1 onboarding of either compound:

Avoid

layer cautiously. Once the user establishes modafinil baseline (week 4-8), 200mg paraxanthine + theanine layered on modafinil days is reasonable — and may ac…

PM dosing past 6h pre-bed:

Avoid

even paraxanthine's shorter half-life produces residual A1/A2A blockade at sleep onset. Respect the cutoff.

Hard-spar Saturdays:

Avoid

same caveat as caffeine — combat sport reaction-consistency literature (Diaz-Lara) hasn't been replicated for paraxanthine, but no mechanistic reason to expe…

Quality Indicators

✓

Tested third-party COA

Reputable brands publish a Certificate of Analysis for identity, potency, and contaminant testing.

✓

GMP-certified manufacturing

Look for cGMP / NSF / USP certifications on the label.

Proprietary blends

Avoid products that hide individual ingredient amounts inside a "proprietary blend."

✗

No origin or sourcing info

Unbranded or no-COA capsules from anonymous sellers carry quality and adulteration risk.

What to Expect

Week 1
Baseline tolerability. Most chronic-use supplements have no acute signal.
Week 2-4
Subtle baseline shift — sleep quality, mood, recovery markers.
Week 4-8
Reach steady state. Re-assess subjective + objective markers.
Month 3+
Long-term maintenance dose if benefit confirmed; otherwise stop.

Side Effects & Safety 8

Side Effects

1Mild GI upset — same gastric-acid stimulation as caffeine, typically lower magnitude. Take with light food if persistent.
2Diuresis — modest, similar to caffeine. Compensate with electrolytes (V4 already covers).
3Mild HR rise — typically 3-8 bpm at 200mg dose (vs 5-15 bpm for equivalent caffeine). Universally present; benign in CV-healthy 20yo.
4Sleep onset delay if dosed too late — even with 6h cutoff, some users report subjective sleep onset latency increase. Track with Oura if available.
5Headache — both rebound (post-cessation) and direct (during use, rare). Less rebound than caffeine, but not zero.
6Anxiety / racing thoughts — esp. anxiety-prone users, esp. doses >300mg. Theanine pairing mitigates substantially. ADORA2A TT carriers may experience this even at 200mg.
7Mild palpitations — mostly benign; concerning only if persistent or with chest pain.
8Tolerance development within 1-2 weeks of daily dosing — mechanistically identical to caffeine.

When to Stop

Long-term safety data is essentially absent. ENFINITY received GRAS status in 2022 based on short-term safety studies. There is no 6-month, 12-month, or chronic-use safety database in humans yet. This is the single most important caveat for paraxanthine vs caffeine — caffeine has 100+ years of human exposure data; paraxanthine has 4-5 years of supplement-grade exposure plus a lifetime of intra-human caffeine-metabolite exposure.
Theoretical arrhythmia risk — same class as caffeine; rare in healthy young adults; relevant only with pre-existing arrhythmia or very high doses.
Theoretical caffeine-class anxiety / sleep disorder — DSM-5 caffeine criteria likely apply by analogy.
Drug interactions — see Drug interactions section. Generally lower interaction surface than caffeine due to non-CYP1A2 clearance.
First 14 days: standard methylxanthine titration. Monitor HR/BP, GI tolerance, sleep architecture (Oura).
First 30 days: flag tolerance development. If subjective effect at 200mg is meaningfully reduced by week 3-4, increase rest days rather than dose.
First 6 months of regular use: Oura sleep architecture audit. Same subjective-objective disconnect risk as caffeine.